Ablation of hepatocyte derived-FGL1 does not aggravate metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma
Jean Personnaz, Lisa Cannizzo, Céline Marie Pauline Martin, Aurore Desquesnes, Manon Sotin, Joanna DaSilva, Prunelle Perrier, Hervé Guillou, Léon Kautz
This study shows that ablating FGL1 in hepatocytes does not worsen MASLD or HCC, despite increased glucose and metabolic changes in western diet-fed mice.
The FASEB Journal · Aug 20, 2025Peer-reviewedPathology